Agios has filed to raise $150 million in a follow-on offering, positioning it to add to the $512 million in cash it sat on as of the end of June.

Alzheimer’s specialist AC Immune, which lists Biogen, Genentech and Johnson & Johnson among its partners, has set the terms for its long-mooted Nasdaq IPO.

Third Rock Ventures’ Relay Therapeutics has broken from its 12-month stealth mode with a $57 million Series A cash boost as it looks to create a next-…

A startup based on the work of gene therapy pioneer Nathalie Cartier-Lacave has secured Series A funds to advance programs against Huntington's and…

The VC wing of Novartis has joined with Fountain Healthcare Partners to lead a $17 million round in Inflazome, a chronic inflammatory disease startup.

Adienne is planning an IPO in Switzerland to fund the advance if its graft-versus-host disease drug over the regulatory finish line.

Finally following in the wake of Editas and Intellia, CRISPR Therapeutics has decided to buck the tumultuous 2016 IPO trend by going public with its highly…

In a year when many smaller biotechs have had to ditch their public offerings entirely, Novan may count itself lucky it can go for an IPO at all, despite…

Pfizer, along with Orion Equity Partners and JDRF, is betting $4 million on a startup that is seeking to use targeted nanoparticle tolerance therapeutics…